Pharma Pulse 2/18/25: PharmExec's 20th Annual 2025 Pipeline Report, Patient Journey and the Role of the Pharmacist & more
The latest news for pharma industry insiders.
2025 Pipeline Report: The Edge of Greatness?
The biopharmaceutical industry has long been at the forefront of innovation. From the rise of precision medicine, to artificial intelligence technologies accelerating drug development, to the advent of small-molecule drugs, recent revolutions in pharmaceuticals are delivering better results for patients and more options for drug manufacturers.
Now, emerging developments in antibody-drug conjugates (ADCs) for oncology; hopeful treatments on the rise for idiopathic pulmonary fibrosis (IPF), a long-elusive disease to target; the transforming—and overarching—promise of GLP-1 agonists; growing investment around advanced therapy medicinal products (ATMPs); and a concerted push for new approaches in antibiotics are challenging the boundaries of what’s possible.
Pharmaceutical Executive’s 20th Annual Pipeline Report profiles the most promising activity and efforts in development across these five therapeutic areas.
Patient Journey and the Role of the Pharmacist
Panelists discuss how the TD patient journey often begins with subtle symptoms that may go unrecognized, particularly in older adults who face unique challenges with diagnosis and treatment, while emphasizing the crucial role pharmacists play in early identification through medication reviews, regular monitoring of patients on antipsychotics, coordination with healthcare providers, and ongoing assessment of treatment response and adherence.
Irish Exports Hit Record in 2024 on Medical, Pharma Goods
Irish exports hit a record level in 2024, according to new data, largely driven by a boost in medical and pharmaceutical products being sent abroad.
New ‘Super Test’ for Prostate Cancer Developed in the UK by EDX Medical
Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionize screening and diagnosis of the disease and accelerate personalized treatment for patients.
The test identifies the presence or absence of cancerous cells, signs of early and late-stage cancer, whether it is slow or aggressive as well as genetic and hereditary risks in the patient. It also involves studying the most comprehensive combination of clinically-validated prostate-related biomarkers currently known, in both blood and urine samples. The interpretation of these biomarkers using a proprietary AI-driven algorithm highlights early signs of cancer and characteristic features that can guide treatment selection.
As many of you know, the Centers for Medicare & Medicaid Services is fresh off revealing its choices for the 15 latest drugs to be covered under Part D for price negotiations. Headlining that list is Ozempic, Novo Nordisk's branded semaglutide—which is a type of glucagon-like peptide-1 (GLP-1) receptor agonist. In my editor's note for the Feb issue of Pharmaceutical Commerce Magazine, I dug a little deeper into the drug class phenomenon that reveals some interesting takeaways on a smaller subgroup of users.
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
